Park Plaza Riverbank London Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2016
Here are the related meetings in 2019:
Molecular Approaches to Vaccines and Immune Monitoring (J5)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Translational Vaccinology for Global Health (S1)
Organizer(s) Christopher L. Karp, Gagandeep Kang and Rino Rappuoli
October 25—29, 2016
Park Plaza Riverbank London • London, UK
Discounted Abstract Deadline: Jun 27, 2016
Abstract Deadline: Jul 26, 2016
Scholarship Deadline: Jun 27, 2016
Discounted Registration Deadline: Sep 8, 2016
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.
Summary of Meeting:
The time required to launch new global health vaccines is too long and the late failure rate is unsustainably high. Key barriers include insufficient diversity and quality of preclinical concepts and candidates, immunobiological ignorance, and a lack of understanding of correlates or mechanisms of protection. Root causes include siloed science and linear thinking; poor integration across the discovery/development/delivery ecosystem; and slow entry and limited throughput in early human proof of concept testing. This Keystone Symposia meeting aims to bring together those pioneering novel, creative solutions to these problems of global vaccine discovery and development across the academic/biotech/product development partner/pharma spectrum.
View Scholarships/Awards
The time required to launch new global health vaccines is too long and the late failure rate is unsustainably high. Key barriers include insufficient diversity and quality of preclinical concepts and candidates, immunobiological ignorance, and a lack of understanding of correlates or mechanisms of protection. Root causes include siloed science and linear thinking; poor integration across the discovery/development/delivery ecosystem; and slow entry and limited throughput in early human proof of concept testing. This Keystone Symposia meeting aims to bring together those pioneering novel, creative solutions to these problems of global vaccine discovery and development across the academic/biotech/product development partner/pharma spectrum.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Tuesday, October 25 with registration from 16:00 to 20:00. Conference events conclude on Saturday, October 29 with a closing plenary session and keynote address from 13:30 to 19:00, followed by a social hour and entertainment. We recommend return travel on Sunday, October 30 in order to fully experience the meeting.
TUESDAY, OCTOBER 25
WEDNESDAY, OCTOBER 26
THURSDAY, OCTOBER 27
FRIDAY, OCTOBER 28
SATURDAY, OCTOBER 29
SUNDAY, OCTOBER 30
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Tuesday, October 25 with registration from 16:00 to 20:00. Conference events conclude on Saturday, October 29 with a closing plenary session and keynote address from 13:30 to 19:00, followed by a social hour and entertainment. We recommend return travel on Sunday, October 30 in order to fully experience the meeting.
TUESDAY, OCTOBER 25
08:30—11:30
Controlled Human Infection Models
Meeting has ended...abstracts no longer viewable online.
*
Gagandeep Kang,
Christian Medical College/Translational Health Science and Technology Institute, India
Robert Sauerwein,
Radboud University, Netherlands
Protection and Immune Responses in Malaria after Whole Sporozoite Immunization
Protection and Immune Responses in Malaria after Whole Sporozoite Immunization
Andrew J. Pollard,
University of Oxford, UK
Insights into the Biology of Enteric Fever and Typhoid Vaccine Efficacy Using Experimental Human Challenge with Typhoidal Salmonellae
Insights into the Biology of Enteric Fever and Typhoid Vaccine Efficacy Using Experimental Human Challenge with Typhoidal Salmonellae
Coffee Break
Anna P. Durbin,
Johns Hopkins Bloomberg School of Public Health, USA
The Dengue Human Infection Model: A Tool to Advance Vaccine Development and the Search for Immune Correlates of Protection
The Dengue Human Infection Model: A Tool to Advance Vaccine Development and the Search for Immune Correlates of Protection
Daniela M. Ferreira,
Liverpool School of Tropical Medicine, UK
Short Talk: Controlled Human Co-Infection with Live Attenuated Influenza Vaccine (LAIV) and Pneumococcus
Short Talk: Controlled Human Co-Infection with Live Attenuated Influenza Vaccine (LAIV) and Pneumococcus
Hedda Wardemann,
German Cancer Research Center, Germany
Short Talk: Development and Clonal Evolution of Human Anti-CSP Memory B Cell Antibody Responses
Short Talk: Development and Clonal Evolution of Human Anti-CSP Memory B Cell Antibody Responses
13:30—15:30
Joint Session with Grand Challenges and Keystone Symposia
Meeting has ended...abstracts no longer viewable online.
UK & Global Innovations to Achieve the Sustainable Development Goals
Emcee: Chris Karp, Bill & Melinda Gates Foundation
Jeremy Farrar, Wellcome Trust
Welcome Address
Spotlight Speaker: Clare Elwell
Biomarkers of Nutrition Related Cognitive Development
Floriane Fidegnon-Edoh, Ursuline Academy
Keynote Conversation: Leadership in Science & Innovation - Good for Britain, Good for the World
Bill Gates, Bill & Melinda Gates Foundation
Opening Remarks
Moderator: Natasha Kaplinsky
Bill Gates, Bill & Melinda Gates Foundation
Minister Priti Patel, Secretary of State for International Development, UK
Sir Richard Branson, Virgin Group
Closing Remarks
Trevor Mundel, Bill & Melinda Gates Foundation
Gayle E. Smith, USAID (Video Address)
Emcee: Chris Karp, Bill & Melinda Gates Foundation
Jeremy Farrar, Wellcome Trust
Welcome Address
Spotlight Speaker: Clare Elwell
Biomarkers of Nutrition Related Cognitive Development
Floriane Fidegnon-Edoh, Ursuline Academy
Keynote Conversation: Leadership in Science & Innovation - Good for Britain, Good for the World
Bill Gates, Bill & Melinda Gates Foundation
Opening Remarks
Moderator: Natasha Kaplinsky
Bill Gates, Bill & Melinda Gates Foundation
Minister Priti Patel, Secretary of State for International Development, UK
Sir Richard Branson, Virgin Group
Closing Remarks
Trevor Mundel, Bill & Melinda Gates Foundation
Gayle E. Smith, USAID (Video Address)
08:30—11:30
Human Immune Profiling
Meeting has ended...abstracts no longer viewable online.
*
Lynda M. Stuart,
Bill & Melinda Gates Foundation, USA
Galit Alter,
Ragon Institute of MGH, MIT and Harvard, USA
A Systems Level Approach to Defining Humoral Mechanisms of HIV Control
A Systems Level Approach to Defining Humoral Mechanisms of HIV Control
Mario Roederer,
NIAID, National Institutes of Health, USA
Integrating High-Content Technologies for Cellular Analysis
Integrating High-Content Technologies for Cellular Analysis
Coffee Break
Beate Kampmann,
Imperial College School of Medicine/MRC Gambia, UK
Correlates of Protection for Maternal Immunization: A Way Forward?
Correlates of Protection for Maternal Immunization: A Way Forward?
Leticia Kuri-Cervantes,
University of Pennsylvania, USA
Short Talk: Immune Correlates to Butantan-DV/NIH-TV003 Dengue Vaccine
Short Talk: Immune Correlates to Butantan-DV/NIH-TV003 Dengue Vaccine
Darragh Duffy,
Institut Pasteur, France
Short Talk: Milieu Interieur – Defining the Boundaries of a Healthy Immune Response through Standardized Immunophenotyping
Short Talk: Milieu Interieur – Defining the Boundaries of a Healthy Immune Response through Standardized Immunophenotyping
13:30—15:30
Workshop 1: Correlates of Protection
*
Penny M. Heaton,
Bill & Melinda Gates Medical Research Institute, USA
Correlates of Protection for Vaccine Discovery and Development
Correlates of Protection for Vaccine Discovery and Development
Gemma Moncunill,
ISGlobal, Spain
Immune Correlates Associated with RTS,S/AS01E Malaria Vaccination in a Pediatric Phase III Trial in Africa
Immune Correlates Associated with RTS,S/AS01E Malaria Vaccination in a Pediatric Phase III Trial in Africa
Raquel Furtado,
Albert Einstein College of Medicine, USA
Defining Novel Immune Correlates of Protection in Human Malaria Using Time-of-Flight Cytometry (CyTOF) and Antibody Functional Analyses
Defining Novel Immune Correlates of Protection in Human Malaria Using Time-of-Flight Cytometry (CyTOF) and Antibody Functional Analyses
Robert Mauro DiFazio,
Stanford Medicine, USA
Serial PET-CT Imaging Predicts Vaccine Efficacy Against Tuberculosis in the Non-Human Primate Model
Serial PET-CT Imaging Predicts Vaccine Efficacy Against Tuberculosis in the Non-Human Primate Model
Sophie Rhodes,
London School of Hygiene and Tropical Medicine, UK
Use of Mathematical Modelling for Dose Finding in T Cell-Mediated Vaccines
Use of Mathematical Modelling for Dose Finding in T Cell-Mediated Vaccines
16:00—18:30
Toward PK/PD in B Cell Vaccinology
Meeting has ended...abstracts no longer viewable online.
*
Chris Wilson,
, USA
Michael G. McHeyzer-Williams,
The Scripps Research Institute, USA
Reprogramming B Cell Memory
Reprogramming B Cell Memory
Arup K. Chakraborty,
Massachusetts Institute of Technology, USA
Modeling Selection Forces during Antibody Affinity Maturation
Modeling Selection Forces during Antibody Affinity Maturation
W. Ripley Ballou,
GlaxoSmithKline Vaccines, USA
Optimizing Somatic Hypermutation? An Intriguing Observation from the Clinic
Optimizing Somatic Hypermutation? An Intriguing Observation from the Clinic
John T. Schiller,
National Cancer Institute, National Institutes of Health, USA
HPV VLP Vaccines: Asymtoting to a Single Dose?
HPV VLP Vaccines: Asymtoting to a Single Dose?
Monia Bardelli,
GlaxoSmithKline, Italy
Short Talk: Profiling the Molecular Mechanisms that Drive the Fate of Human B Cells in Response to Vaccination
Short Talk: Profiling the Molecular Mechanisms that Drive the Fate of Human B Cells in Response to Vaccination
18:30—19:30
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:30—11:30
T Cells
Meeting has ended...abstracts no longer viewable online.
*
Karen S. Anderson,
Arizona State University, USA
Louis J. Picker,
Oregon Health & Science University, USA
Cytomegalovirus Vectors: Exploiting Viral Control of the CD8+ T Cell Epitope Targeting
Cytomegalovirus Vectors: Exploiting Viral Control of the CD8+ T Cell Epitope Targeting
Bette Tina Marie Korber,
Los Alamos National Laboratory, USA
Epigraph Vaccine Designs for Variable Pathogens
Epigraph Vaccine Designs for Variable Pathogens
Coffee Break
D. Branch Moody,
Brigham and Women's Hospital, USA
Beyond the MHC: Activation of T Cells by CD1 and M. tuberculosis Lipids
Beyond the MHC: Activation of T Cells by CD1 and M. tuberculosis Lipids
Andrew J. McMichael,
Oxford University, UK
HLA-E-Restricted CD8 T Cells
HLA-E-Restricted CD8 T Cells
Denise L. Doolan,
James Cook University, Australia
Short Talk: Rational Vaccine Design against Complex Pathogens using Genomic Sequence
Short Talk: Rational Vaccine Design against Complex Pathogens using Genomic Sequence
13:30—15:30
Workshop 2: Human Immunophenotyping
*
Mark M. Davis,
Stanford University School of Medicine, USA
Systems Immunology and Vaccine Development
Systems Immunology and Vaccine Development
Margherita Coccia,
GlaxoSmithKline Vaccines, Belgium
Mass Cytometry Analysis of a Mosquirix™ Controlled Human Malaria Challenge Trial: A Multivariate Approach
Mass Cytometry Analysis of a Mosquirix™ Controlled Human Malaria Challenge Trial: A Multivariate Approach
Christine Dahlke,
University Medical Center Hamburg-Eppendorf, Germany
The rVSV-Vaccine Platform: Comprehensive Analysis of Immunogenicity against Vector and Insert following rVSV-Vectored Ebola Vaccination
The rVSV-Vaccine Platform: Comprehensive Analysis of Immunogenicity against Vector and Insert following rVSV-Vectored Ebola Vaccination
Tracey Day,
Infectious Disease Research Institute, USA
First-in-Human Evaluation of Safety and Immunogenicity of the Tetravalent Mycobacterium tuberculosis Vaccine, ID93+GLA-SE
First-in-Human Evaluation of Safety and Immunogenicity of the Tetravalent Mycobacterium tuberculosis Vaccine, ID93+GLA-SE
Florian Rubelt,
Stanford University, USA
Distinctive Differences in B and T Cell Receptor Repertoire and Cell Frequencies Are Evident in Individual Immune Responses
Distinctive Differences in B and T Cell Receptor Repertoire and Cell Frequencies Are Evident in Individual Immune Responses
Eita Sasaki,
National Institute of Infectious Disease, Japan
Establishment of a Novel Safety Evaluating System for Vaccines and Adjuvants Using the Genes Expression Profile and Statistical Model
Establishment of a Novel Safety Evaluating System for Vaccines and Adjuvants Using the Genes Expression Profile and Statistical Model
Gianna Triller,
German Cancer Research Center, Germany
Single-Cell Analysis of Rare Memory B Cell Antibodies to Natural Human Malaria Infection
Single-Cell Analysis of Rare Memory B Cell Antibodies to Natural Human Malaria Infection
16:00—18:45
Novel Approaches to Antigen Identification and Immunogen Design
Meeting has ended...abstracts no longer viewable online.
*
Rino Rappuoli,
GlaxoSmithKline Vaccines, Italy
Ashley J. Birkett,
PATH, USA
Development of Vaccines for Malaria Parasite Elimination and Eradication: The Role of Monoclonal Antibodies in Accelerating Development
Development of Vaccines for Malaria Parasite Elimination and Eradication: The Role of Monoclonal Antibodies in Accelerating Development
Peter D. Kwong,
NIAID, National Institutes of Health, USA
Structure-Based Design of Fusion-Glycoprotein Vaccines for Paramyxoviruses
Structure-Based Design of Fusion-Glycoprotein Vaccines for Paramyxoviruses
Louis Schofield,
James Cook University, Australia
Carbohydrate-Based Vaccines for Malaria
Carbohydrate-Based Vaccines for Malaria
Florian Krammer,
Icahn School of Medicine at Mount Sinai, USA
Towards a Universal Influenza Virus Vaccine
Towards a Universal Influenza Virus Vaccine
Masaru Kanekiyo,
NIAID, National Institutes of Health, USA
Short Talk: Vaccine-Induced Broad and Potent Influenza H1N1 Neutralizing Antibody Targets a Novel Viral Site of Vulnerability in the Hemagglutinin Head Domain
Short Talk: Vaccine-Induced Broad and Potent Influenza H1N1 Neutralizing Antibody Targets a Novel Viral Site of Vulnerability in the Hemagglutinin Head Domain
Kizzmekia S. Corbett,
NIAID, National Institutes of Health, USA
Short Talk: Immunogenicity of MERS Coronavirus Spike Trimer Vaccine
Short Talk: Immunogenicity of MERS Coronavirus Spike Trimer Vaccine
18:45—19:45
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:30—11:30
Adjuvants, Mucosal and Otherwise
Meeting has ended...abstracts no longer viewable online.
*
Anna P. Durbin,
Johns Hopkins Bloomberg School of Public Health, USA
Gagandeep Kang,
Christian Medical College/Translational Health Science and Technology Institute, India
Mucosal Barriers to Oral Vaccination in Developing Countries
Mucosal Barriers to Oral Vaccination in Developing Countries
Ulrich H. Von Andrian,
Harvard Medical School, USA
Induction of Mucosal Immune Responses
Induction of Mucosal Immune Responses
Coffee Break
Arnaud Marchant,
Université libre de Bruxelles, Belgium
Impact of Adjuvants on the Functional Program of Vaccine-Induced T Lymphocytes
Impact of Adjuvants on the Functional Program of Vaccine-Induced T Lymphocytes
Aideen C. Allen,
Institut de Pharmacologie et de Biologie Structurale, France
Short Talk: Exploiting Synergy between STING and TLR Agonists as Adjuvants for a Pertussis Vaccine
Short Talk: Exploiting Synergy between STING and TLR Agonists as Adjuvants for a Pertussis Vaccine
Wivine Burny,
GlaxoSmithKline, Belgium
Short Talk: Early Responses to Adjuvanted Vaccination in Humans: Relationships with Adaptive Responses
Short Talk: Early Responses to Adjuvanted Vaccination in Humans: Relationships with Adaptive Responses
13:30—15:30
Clinical Trial Readouts
Meeting has ended...abstracts no longer viewable online.
*
W. Ripley Ballou,
GlaxoSmithKline Vaccines, USA
Carolyn E. Clark,
Norwegian Institute of Public Health, Norway
The rVSV-Vectored Ebola Vaccine: Fast-tracked Clinical Testing during the 2014-15 Epidemic
The rVSV-Vectored Ebola Vaccine: Fast-tracked Clinical Testing during the 2014-15 Epidemic
Thomas Heineman,
GlaxoSmithKline Vaccines, USA
Herpes Zoster Subunit Vaccine - Overcoming Immunosenescence in the Elderly
Herpes Zoster Subunit Vaccine - Overcoming Immunosenescence in the Elderly
Neil Ferguson,
Imperial College London, UK
Modelling the Efficacy Profile of the Sanofi Dengue Vaccine: Implications for Use
Modelling the Efficacy Profile of the Sanofi Dengue Vaccine: Implications for Use
Leo Swadling,
University of Oxford, UK
Short Talk: Potent Virally Vectored T-Cell Vaccines Fail to Reconstitute an Effective HCV-Specific T-Cell Response during Chronic Infection
Short Talk: Potent Virally Vectored T-Cell Vaccines Fail to Reconstitute an Effective HCV-Specific T-Cell Response during Chronic Infection
16:00—17:45
Accelerating Global Health Vaccine R&D
Meeting has ended...abstracts no longer viewable online.
*
Christopher L. Karp,
Bill & Melinda Gates Foundation, USA
Rino Rappuoli,
GlaxoSmithKline Vaccines, Italy
Reverse Vaccinology 2.0: Human Immunology Instructs Vaccine Antigen Design
Reverse Vaccinology 2.0: Human Immunology Instructs Vaccine Antigen Design
Karen S. Anderson,
Arizona State University, USA
Frontiers of T Cell Epitope Prediction/Discovery for Cancer Vaccines
Frontiers of T Cell Epitope Prediction/Discovery for Cancer Vaccines
Rafi Ahmed,
Emory University School of Medicine, USA
Antibody Repertoires in Vaccinated Populations
Antibody Repertoires in Vaccinated Populations
17:45—18:30
Closing Keynote Address
Meeting has ended...abstracts no longer viewable online.
Chris Wilson,
, USA
Collaboration Across Traditional Boundaries to Accelerate Global Health Vaccine R&D
Collaboration Across Traditional Boundaries to Accelerate Global Health Vaccine R&D
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsor for generously supporting this meeting:
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Development, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676 |
